Skip to search formSkip to main contentSkip to account menu

Bezafibrate

Known as: Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-, Bezafibratum, 2-(P-(2-(P-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid 
An agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity. Bezafibrate decreases triglyceride levels… 
National Institutes of Health

Related topics

Related topics

16 relations

Narrower (7)

AM 49Beza-LandeBeza-PurenBezalip
BéfizalIn Bloodagonistsanalogs & derivatives

Broader (1)

Hypolipidemic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
[Improvement in diabetes control by treatment with bezafibrate].
380 diabetic patients with hyperlipidaemia and undergoing treatment with sulphonylureas or insulin were given 200 mg bezafibrate… 
2004
2004
Benzafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal β-oxidation in rat white adipose tissue
Rats treated with bezafibrate, a PPAR activator, gain less body weight and increase daily food intake. Previously, we have… 
2003
2003
Efficacy of bezafibrate in a patient with primary sclerosing cholangitis
on these observations, we diagnosed typical localized PSC of the intrahepatic bile ducts. We additionally diagnosed idiopathic… 
2002
2002
Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports)
noted between collagenous colitis and either hepatitis C or dermatomyositis. This is the first known report of a patient with… 
Review
2001
Review
2001
Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C
1. Wong VS, Hughes V, Trull A, et al. Serum hyaluronic is a useful marker of liver fibrosis in chronic hepatitis C virus… 
1987
1987
Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins. Studies in mild to moderate hypertriglyceridemic patients.
Low density lipoproteins (LDL) of untreated moderate to severe hypertriglyceridemic patients (HTG-LDL) are smaller in size and… 
1986
1986
Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients.
Eighteen hypercholesterolaemic patients have been treated for four months with bezafibrate 200 mg thrice daily. After one month… 
1984
1984
[Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function].
A muscular syndrome has been described in patients on clofibrate and fenofibrate therapy. The present paper describes four… 
1980
1980
Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
The effect of a six-month treatment with bezafibrate on HDL2 and HDL3, measured as cholesterol and apolipoprotein A-I, was… 
1978
1978
Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia
: In a randomized block-trial the comparative efficacy and side-effects of clofibrate (2 X 1 g), placebo and bezafibrate (3 X 150…